# Consensus vs Unlearn.AI

Consensus records 6,014,388 monthly visits with -1.2% month-over-month growth and Freemium pricing. Unlearn.AI records 17,107 monthly visits with -32.5% growth and Contact for Pricing pricing.

| Metric | [Consensus](https://openaitools.app/tool/consensus) | [Unlearn.AI](https://openaitools.app/tool/unlearn-ai) |
| :--- | :--- | :--- |
| Website URL | https://consensus.app | https://unlearn.ai |
| Categories | AI Search Engine, AI Research Tool, AI Papers, AI Article Summarizer | AI Healthcare, AI Research Tool, AI Predictions, AI Models |
| Pricing Model | Freemium | Contact for Pricing |
| Monthly Visits | 6,014,388 | 17,107 |
| MoM Growth Rate | -1.2% | -32.5% |
| Primary Market | United States | United States |
| Direct Visits | 2,918,713 | 7,493 |
| Review Score | 4.7 | 4.4 |
| Saved Count | 31 | 1 |
| Supported Platforms | Website | Website |

## Consensus

Consensus works like a scholarly search engine supercharged by AI. Instead of returning a flat list of PDFs, you ask a natural-language research question and Consensus extracts claims from relevant papers, then shows you what the studies actually find. A Consensus Meter summarizes the weight of evidence for yes/no questions, so you can see at a glance whether scientists largely agree, disagree, or remain divided.

The platform indexes hundreds of millions of peer-reviewed papers spanning medicine, biology, psychology, economics and more. Answers link straight back to the source studies, and you can filter by study design, journal quality, sample size and publication year to separate stronger evidence from weaker signals. Features like Deep Search, Topic Synthesis and Skills let researchers build a working knowledge base over time rather than starting from scratch on every query.

Consensus is designed for researchers, clinicians, students and analysts who need trustworthy signals from the scientific record without drowning in irrelevant results. A free tier gives limited AI-powered searches each month, while paid plans unlock unlimited use, advanced filters and deeper synthesis.

**Pricing & Plans:** Freemium. A free tier offers a limited number of AI-powered searches per month; paid individual plans unlock unlimited searches and advanced research features, with discounted student pricing and team/enterprise options.

- **Evidence-grounded answers:** Ask a research question in plain language and get answers synthesized from peer-reviewed studies, with each claim linked to its source paper.
- **Consensus Meter:** A visual summary shows how the scientific literature leans on a yes/no question, indicating agreement, disagreement or mixed evidence.
- **Powerful filters:** Narrow results by study design, sample size, journal quality, publication year and more to prioritize high-quality evidence.
- **Topic synthesis and Deep Search:** Aggregate findings across many studies into structured summaries that map what is known and where the gaps are.
- **Research workspace:** Save papers, organize sources and build a persistent knowledge base for literature reviews and ongoing projects.

**Strengths:** Answers cite real peer-reviewed papers, so claims are verifiable; Consensus Meter makes it easy to gauge scientific agreement at a glance; Rich filters help separate high-quality evidence from weaker studies; Fast, clean interface designed around research workflows

**Limitations:** Free tier caps the number of AI-assisted searches per month; Coverage is strongest for STEM and health fields, lighter for some humanities topics; It guides you toward sources but is not a substitute for reading full papers

[Profile (Markdown)](https://openaitools.app/tool/consensus.md)

## Unlearn.AI

Unlearn.AI works with biopharma sponsors and clinical research teams at three points in a trial's lifecycle: before the protocol is finalized, while the study is running, and after readout. In design, teams model the patients they expect to enroll and pressure-test sample size, eligibility criteria, endpoints, and comparators before locking the protocol. The company's PROCOVA method — described as EMA-qualified and FDA-supported — applies twin-based covariate adjustment to reduce sample size in randomized controlled trials while holding statistical power, or to increase power without adding patients.

Mid-study, Unlearn supports pre-specified twin-based analyses that tighten interim estimates without enrolling anyone new, and lets teams re-run design scenarios when new evidence — a competitor readout, a fresh publication, or blinded data drifting from assumptions — changes the picture. After a study reads out, digital twins are used to contextualize population, endpoints, and variability, improving sensitivity across endpoints and helping teams re-evaluate historical trial data with regulatory-aligned methods.

Unlearn publishes concrete case outcomes: a 20% sample-size reduction built into a Phase 1/2 design with roughly $2M in savings, a 33% smaller control arm and four-plus months of enrollment time saved in a re-analysis of completed Phase 3 trials from a top-5 global sponsor, and a completed Phase 3 ALS trial re-analyzed to keep full power with 92 fewer participants. The company partners with sponsors including Trace Neuroscience, QurAlis, Acumen Pharmaceuticals, SOLA Biosciences, VectorY Therapeutics, and CHDI Foundation, and states it works with top global pharma companies. Unlearn does not publish list pricing; engagements are scoped through direct contact.

**Pricing & Plans:** Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team.

- **AI-generated patient digital twins:** Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
- **PROCOVA design and analysis method:** A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
- **Trial design scenario modeling:** Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
- **Interim and readout analysis support:** Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
- **Externally controlled study design:** Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.

**Strengths:** Digital twins are generated from data already collected, so no extra patients are required to gain information; Publicly reported, quantified outcomes — sample-size reductions, cost savings, and enrollment time saved — rather than only qualitative claims; Covers the whole trial lifecycle: design, interim, and readout, not just one decision point; Named collaborations with biotech and pharma sponsors, plus regulatory-aligned methodology

**Limitations:** Pricing is not published, so budgeting requires a direct sales conversation; The value proposition depends on regulatory acceptance of twin-based methods, which varies by agency and indication; Best suited to sponsors with existing clinical data and statistical teams; not a self-serve tool; Public metrics come from specific studies and may not transfer directly to other indications

[Profile (Markdown)](https://openaitools.app/tool/unlearn-ai.md)

## Frequently Asked Questions

### How do Consensus and Unlearn.AI compare in monthly traffic?

Consensus has 6,014,388 monthly visits, while Unlearn.AI has 17,107. Traffic estimates describe audience size, not product quality.

### How do their growth rates compare?

Consensus has a month-over-month growth rate of -1.2%; Unlearn.AI has -32.5%.

### How does pricing compare?

Consensus: Freemium. Freemium. A free tier offers a limited number of AI-powered searches per month; paid individual plans unlock unlimited searches and advanced research features, with discounted student pricing and team/enterprise options. Unlearn.AI: Contact for Pricing. Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team.

## Alternatives

| # | Tool Name | Monthly Visits | MoM Growth Rate | Pricing Model | Summary | Profile (Markdown) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 1 | [Perplexity](https://openaitools.app/tool/perplexity-ai) | 88,310,223 | -3.7% | Freemium | Covers general web sources alongside academic papers, but lacks specialized scientific synthesis metrics and consensus ratings. | [.md](https://openaitools.app/tool/perplexity-ai.md) |
| 2 | [Semantic Scholar](https://openaitools.app/tool/semantic-scholar) | 8,198,672 | +5.8% | Free | Completely free access to a massive scholarly index, but offers less automated natural-language evidence synthesis than Consensus. | [.md](https://openaitools.app/tool/semantic-scholar.md) |
| 3 | [Kagi Search](https://openaitools.app/tool/kagi-search) | 4,647,605 | +3.2% | Free Trial, Paid | A paid, ad-free search engine that answers to its users | [.md](https://openaitools.app/tool/kagi-search.md) |
| 4 | [SciSpace](https://openaitools.app/tool/scispace) | 4,464,111 | +8.6% | Freemium | Provides deeper PDF reading and interactive literature analysis tools, but is less focused on quick evidence aggregation. | [.md](https://openaitools.app/tool/scispace.md) |
| 5 | [Elicit](https://openaitools.app/tool/elicit) | 1,751,507 | +3.1% | Freemium | Performs advanced systematic review data extraction and evidence synthesis, but has a more complex interface than Consensus. | [.md](https://openaitools.app/tool/elicit.md) |
| 6 | [Jenni](https://openaitools.app/tool/jenni) | 1,498,133 | +5.2% | Freemium | The AI workspace where researchers read, write, and cite with every claim traceable to its source | [.md](https://openaitools.app/tool/jenni.md) |
| 7 | [Rayyan](https://openaitools.app/tool/rayyan) | 1,116,437 | +7.9% | Freemium | AI-assisted systematic review software for screening, extraction, and evidence synthesis at scale | [.md](https://openaitools.app/tool/rayyan.md) |
| 8 | [Scite](https://openaitools.app/tool/scite) | 841,974 | +1.1% | Free Trial, Contact for Pricing | Tracks how papers are cited with Smart Citations to gauge reliability, but features a less direct Q&A synthesis. | [.md](https://openaitools.app/tool/scite.md) |
| 9 | [ResearchRabbit](https://openaitools.app/tool/researchrabbit) | 831,571 | +3.1% | Free | Excellent for visual citation mapping and literature discovery, but lacks automated paper Q&A and evidence synthesis. | [.md](https://openaitools.app/tool/researchrabbit.md) |
| 10 | [Connected Papers](https://openaitools.app/tool/connected-papers) | 750,576 | +3.1% | Freemium | Visualizes research connections through interactive graphs for literature discovery, but does not provide direct Q&A synthesis. | [.md](https://openaitools.app/tool/connected-papers.md) |

---
Source: https://openaitools.app/compare/consensus-vs-unlearn-ai

More Markdown: [Categories](https://openaitools.app/categories.md) · [Traffic rankings](https://openaitools.app/rankings.md) · [llms.txt](https://openaitools.app/llms.txt)
